Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 6;25(11):6265.
doi: 10.3390/ijms25116265.

Diagnostic Utility of Selected Matrix Metalloproteinases (MMP-2, MMP-3, MMP-11, MMP-26), HE4, CA125 and ROMA Algorithm in Diagnosis of Ovarian Cancer

Aleksandra Kicman  1 , Ewa Gacuta  2 , Monika Kulesza  3 , Ewa Grażyna Będkowska  4 , Rafał Marecki  5 , Ewa Klank-Sokołowska  6 , Paweł Knapp  6 , Marek Niczyporuk  1 , Sławomir Ławicki  3
Affiliations

Diagnostic Utility of Selected Matrix Metalloproteinases (MMP-2, MMP-3, MMP-11, MMP-26), HE4, CA125 and ROMA Algorithm in Diagnosis of Ovarian Cancer

Aleksandra Kicman et al. Int J Mol Sci. .

Abstract

Ovarian cancer (OC) has an unfavorable prognosis. Due to the lack of effective screening tests, new diagnostic methods are being sought to detect OC earlier. The aim of this study was to evaluate the concentration and diagnostic utility of selected matrix metalloproteinases (MMPs) as OC markers in comparison with HE4, CA125 and the ROMA algorithm. The study group consisted of 120 patients with OC; the comparison group consisted of 70 patients with benign lesions and 50 healthy women. MMPs were determined via the ELISA method, HE4 and CA125 by CMIA. Patients with OC had elevated levels of MMP-3 and MMP-11, similar to HE4, CA125 and ROMA values. The highest SE, SP, NPV and PPV values were found for MMP-26, CA125 and ROMA in OC patients. Performing combined analyses of ROMA with selected MMPs increased the values of diagnostic parameters. The topmost diagnostic power of the test was obtained for MMP-26, CA125, HE4 and ROMA and performing combined analyses of MMPs and ROMA enhanced the diagnostic power of the test. The obtained results indicate that the tested MMPs do not show potential as stand-alone OC biomarkers, but can be considered as additional tests to raise the diagnostic utility of the ROMA algorithm.

Keywords: CA125; HE4; MMP-11; MMP-2; MMP-26; MMP-3; ROMA algorithm; Serous cystadenomas; ovarian cancer; plasma concentration.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
MMP-2 plasma concentrations (with marked median and interquartile range) in all tested groups: patients with ovarian cancer (OC), begin lesion (BL) and healthy subject (HS). MMP-2 concentrations were obtained by ELISA method.
Figure 2
Figure 2
MMP-3 plasma concentrations (with marked median and interquartile range) in all tested groups: patients with ovarian cancer (OC), begin lesion (BL) and healthy subject (HS). MMP-3 concentrations were obtained by ELISA method.
Figure 3
Figure 3
MMP-11 plasma concentrations (with marked median and interquartile range) in all tested groups: patients with ovarian cancer (OC), begin lesion (BL) and healthy subject (HS). MMP-11 concentrations were obtained by ELISA method.
Figure 4
Figure 4
MMP-26 plasma concentrations (with marked median and interquartile range) in all tested groups: patients with ovarian cancer (OC), begin lesion (BL) and healthy subject (HS). MMP-26 concentrations were obtained by ELISA method.
Figure 5
Figure 5
HE4 plasma concentrations (with marked median and interquartile range) in all tested groups: patients with ovarian cancer (OC), begin lesion (BL) and healthy subject (HS). HE4 concentrations were obtained by the CMIA method.
Figure 6
Figure 6
CA125 plasma concentrations (with marked median and interquartile range) in all tested groups: patients with ovarian cancer (OC), begin lesion (BL) and healthy subject (HS). CA125 concentrations were obtained by the CMIA method.
Figure 7
Figure 7
ROMA algorithm values expressed in percentages (with marked median and interquartile range) in patients with ovarian cancer (OC) and begin lesion (BL).
Figure 8
Figure 8
AUC values obtained for all parameters and combinations between parameters.
Figure 9
Figure 9
Flowchart of the study course.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. World Ovarian Cancer Coalition World Ovarian Cancer Coalition Atlas 2023. [(accessed on 17 April 2024)]. Available online: https://worldovariancancercoalition.org/wp-content/uploads/2023/03/World....
    1. Kicman A., Niczyporuk M., Kulesza M., Motyka J., Ławicki S. Utility of Matrix Metalloproteinases in the Diagnosis, Monitoring and Prognosis of Ovarian Cancer Patients. Cancer Manag. Res. 2022;14:3359–3382. doi: 10.2147/CMAR.S385658. - DOI - PMC - PubMed
    1. Atallah G.A., Abd Aziz N.H., Teik C.K., Shafiee M.N., Kampan N.C. New Predictive Biomarkers for Ovarian Cancer. Diagnostics. 2021;11:465. doi: 10.3390/diagnostics11030465. - DOI - PMC - PubMed
    1. Ravindran F., Choudhary B. Ovarian Cancer-Updates in Tumour Biology and Therapeutics. IntechOpen; Rijeka, Croatia: 2021. Ovarian cancer: Molecular classification and targeted therapy; pp. 1–21.
    1. Dilley J., Gentry-Maharaj A., Ryan A., Burnell M., Manchanda R., Kalsi J., Singh N., Woolas R., Sharma A., Williamson K., et al. Ovarian Cancer Symptoms in Pre-Clinical Invasive Epithelial Ovarian Cancer—An Exploratory Analysis Nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) Gynecol. Oncol. 2023;179:123–130. doi: 10.1016/j.ygyno.2023.11.005. - DOI - PMC - PubMed

MeSH terms